



ISODIOL INTERNATIONAL INC. COMMENCES APPROVAL PROCESS FOR ITS PHARMACEUTICAL PRODUCTS THROUGH THE BRAZILIAN HEALTH REGULATORY AGENCY (ANVISA)

June 19, 2017 - Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: LAGBF) (Frankfurt: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has initiated the drug approval process through the Brazilian Health Regulatory Agency (ANVISA) for the approval of its pharmaceutical grade cannabidiol (CBD) products for placement in the Special Category List for approved imported CBD products.

As a part of the ANVISA approval process, the Company is also proud to announce physicians are currently prescribing the Isoderm product. “We are extremely excited to have officially entered the South American market for our pharmaceutical grade products,” said Marcos Agramont, Chief Executive Officer of Isodiol Inc.

“We anticipate receiving full approval within the next quarter, which allows us time to develop and implement our commercialization strategy for the Brazilian market. We will continue to develop products and sale channels in North America for our Nutraceutical products however, as the global CBD market evolves, we want to ensure Isodiol is at the forefront of this movement. As leaders in the domestic space, we will ensure Isodiol has a significant presence in the implementation of global standards with health authorities and government officials in turning this CBD movement into a legitimate industry,” said Marcos.

The company has also signed a non-binding letter of intent for an exclusive partnership agreement with an established Brazilian based pharmaceutical importer and distributor, who will provide the following services,

- Obtain formal ANVISA approval for the products in Brazil,
- Work exclusively with Isodiol for the importation, promotion, development and sale of products,
- Sponsor events for physicians, distributors and pharmaceutical companies to spread awareness, educate and promote products.

Additional information will be provided around the financial terms of the partnership agreement in the coming weeks.

About Isodiol International Inc.

Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in manufacturing and development of consumer products. Isodiol's nutraceutical division is the pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano technology for the highest quality consumable and topical skin



care products.

Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into Latin America, Asia and Europe.

ON BEHALF OF THE BOARD

"Marcos Agramont"

CEO & Director

CORPORATE MEDIA:

ir@isodiol.com

www.isodiol.com

Join Us On Face Book:

<https://www.facebook.com/isodiol/>

Twitter: @isodiol

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.